First, a pricing scandal for Catalyst's Firdapse. Next, off-label competition?
admin 7th May 2019 Uncategorised 0Jacobus for years gave away an unapproved drug to patients with a rare neuromuscular disorder. Then, Catalyst Pharma launched an FDA-approved version at $375,000 a year. Now, Jacobus has won a surprise FDA approval—and Catalyst may lose out to off-label prescriptions.
More: First, a pricing scandal for Catalyst's Firdapse. Next, off-label competition?
Source: fierce